FOR AGENT/BROKER USE ONLY. DO NOT DISTRIBUTE.

Evernorth GeneFocus: Oncology

A new oncology genetic testing solution for identifying inherited cancer risk earlier with accessible genetic testing, provider guidance, and personalized prevention strategies.

doctor with female patient

Helping members understand risk earlier—and act sooner

Evernorth GeneFocus℠: Oncology helps members identify inherited cancer risk before cancer develops or earlier in the disease journey. By pairing genetic insight with education and provider support, the program enables more informed decisions around prevention, screening, and long‑term health. 

What the solution does:

Provides access to hereditary cancer risk genetic testing

Helps identify members with inherited cancer risk who may not qualify under standard testing guidelines

Complements existing medical and pharmacy oncology benefits, including Evernorth Oncology Benefit Services℠

How Evernorth GeneFocus: Oncology works

Employer enrolls for a flat per‑member‑per‑month fee

Members receive education and choose whether to pursue testing

Primary care providers order the test

Testing is completed at home or at a LabCorp location

Results are reviewed with the provider, with guidance on next steps such as screening or prevention

woman in sweater at laptop

Why this matters for clients

Reduce

Reduce avoidable high‑cost cancer events

Improve

Improve treatment effectiveness through earlier intervention

Support

Support better use of health care dollars over time

Strengthen

Strengthen a long‑term, sustainable oncology strategy

Why this matters for members

With personalized genetic insight, members can:

Begin screening earlier or more frequently, when appropriate

Take steps to reduce future cancer risk

Make more informed health decisions with provider guidance

Avoid unnecessary or ineffective care 

Looking ahead

The solution is designed to grow over time, with future enhancements planned across pharmacogenomics, residual disease testing, and tumor profiling—supporting even more personalized oncology care. 

Key date and client action:

July 1, 2026: Oncology genetic testing solution becomes available

Client action: No immediate action required today; consultants can begin positioning the solution with clients focused on prevention‑oriented oncology strategies and long‑term cost management 

Questions? Contact our team.